Clinical trials: CD - Crohn's Disease
Crohn Disease
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term…
- Trial name
- DUET ENCORE-CD (NCT07577843)
- Testing
- JNJ-78934804, Guselkumab
- Where
- 287 sites in United States, Argentina and 28 more
- Volunteers
- 460 people
- Sponsor
- Janssen Research & Development, LLC
Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)
Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
To study the efficacy of different biological treatment on patient with inflammatory bowel disease after one year of treatment in upper egypt
- Trial name
- NCT07495644
- Testing
- adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab
- Volunteers
- 95 people
- Sponsor
- Assiut University
Crohn Disease (CD), Intensification
Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study
Crohn's disease (CD) is a chronic and destructive inflammatory disease of the gastrointestinal tract characterized by phases of relapse and remission.
- Trial name
- OPTIM (NCT07616687)
- Testing
- Guselkumab
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Crohn's Disease
Fibrin Glue for Perianal Fistulas in Crohn's Disease: a Randomized Controlled Trial
This multicenter, randomized, controlled trial was conducted by the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID) to evaluate the efficacy and safety of the injection of fibrin glue in…
- Trial name
- Fibrin glue (NCT00723047)
- Testing
- Fibrin glue injection in fistula
- Where
- 14 sites in Belgium, France
- Volunteers
- 77 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Crohn's Disease
CP-461 for the Treatment of Crohn's Disease
Patients with moderately to severely active Crohn's disease will be treated with oral CP-461 200 mg (2 x 100 mg capsules) twice-daily for 8 weeks.
- Trial name
- NCT00042055
- Testing
- CP-461
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astellas Pharma Inc
IBD - Inflammatory Bowel Disease
Long-term Remission After Ileorectal Anastomosis in Crohn's Disease.
Single-center, retrospective, observational study. The medical records of patients who underwent colectomy and ileorectal anastomosis (IRA) for refractory Crohn's colitis between 1996 and 2016 were reviewed.
- Trial name
- NCT06777043
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Inflammatory Bowel Diseases, Crohn's Disease
Thalidomide in Pediatric Inflammatory Bowel Diseases.
Several open-label studies reported thalidomide efficacy in inducing clinical remission and steroid tapering in refractory Inflammatory Bowel diseases (IBD), both in adults and in children.
- Conditions
- Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis
- Trial name
- TALIBDP (NCT00720538)
- Testing
- Thalidomide
- Where
- 7 sites in Italy
- Volunteers
- 84 people
- Sponsor
- IRCCS Burlo Garofolo
Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), NON-IBD
AI-Enhanced Wide-Field Endoscopic Fluorescence Mapping of Gastrointestinal Mucosal Permeability in IBD - A Pilot Study in IBD Patients and Controls
This pilot study will test a new imaging system that uses fluorescent dye and artificial intelligence (AI) during colonoscopy to measure how "leaky" the lining of the colon is in people with inflammatory bowel disease (IBD).
- Trial name
- NCT07546955
- Testing
- Artificial Intelligence-Enhanced Wide-Field Mucosal Permeability Mapping
- Volunteers
- 70 people
- Sponsor
- Hamilton Health Sciences Corporation
Perianal Fistula, Crohn Disease
Surgical Closure vs Anti-TNF in the Treatment of Perianal Fistulas in Crohn's Disease (PISA-II): a Comprehensive Cohort Design
Currently, the treatment of Crohn's patients with perianal fistulas predominantly exists of anti-TNF medication. However, its efficiency has never been directly compared to surgical closure of the perianal fistula.
- Trial name
- PISA-II (NCT06441526)
- Testing
- anti-tumour necrosis factor α antibodies, Advancement plasty
- Where
- Netherlands
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Crohn Disease
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
- Trial name
- NCT05906576
- Testing
- Infliximab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Crohn's Disease (CD)
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab.
- Trial name
- SEQUENCE (NCT04524611)
- Testing
- Risankizumab, Ustekinumab
- Where
- 300 sites in United States, Argentina and 29 more
- Volunteers
- 527 people
- Sponsor
- AbbVie
Crohn's Disease
Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease
The purpose of this study is to determine the safety and efficacy of interferon beta-1a in maintaining remission in patients with Crohn's disease.
- Trial name
- NCT00304252
- Testing
- Interferon beta-1a
- Where
- 5 sites in Germany, Italy and 3 more
- Volunteers
- 192 people
- Sponsor
- EMD Serono
Crohn's Disease
Monoclonal Antibody Treatment of Crohn's Disease
This study will examine the safety and effectiveness of an experimental drug called J695 for treating patients with Crohn's disease-a long-term recurring inflammation of the small and large intestine.
- Trial name
- NCT00007163
- Testing
- J695
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Crohn's Disease
An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)
The aim of this study is to quantify how infliximab therapy is being used in the UK and the consequent impact on health care resources, which will help to inform budget holders and payers on the costs associated with the…
- Trial name
- NCT00988832
- Testing
- Infliximab
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Moderately to Severely Active Crohn Disease
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and…
- Trial name
- ENHANCE-CD (NCT06456593)
- Testing
- Obefazimod
- Where
- 149 sites in United States, Belgium and 10 more
- Volunteers
- 212 people
- Sponsor
- Abivax S.A.
Crohn's Disease
Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation
The purpose of this study is to evaluate the effects and safety of OPS-2071 (150, 300, or 600 mg twice a day [BID]) versus placebo, as add-on therapy in participants with Crohn's disease who show symptoms of active inflammation…
- Trial name
- NCT03850509
- Testing
- OPS-2071
- Where
- 31 sites in United States, Poland
- Volunteers
- 3 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Interleukin 12, Interleukin 23
Role of IL 12 and IL 23 as Potential Biomarkers in Diagnosis of Early Crohn's Disease
This study aims to evaluate the role of Interleukin (IL)-12 and IL-23 as potential biomarkers in the diagnosis of early Crohn's disease.
- Conditions
- Interleukin 12, Interleukin 23, Biomarker, Diagnosis
- Trial name
- NCT06844565
- Testing
- Immunohistochemistry procedure
- Where
- Egypt
- Volunteers
- 110 people
- Sponsor
- Tanta University
Crohn's Disease, Fistula
The Role of MSC in the Treatment of Fistulas in Patients With Perianal Crohn's Disease
Here investigators will carry out this phase II clinical trial to explore a effective therapeutic regimen of MSC in the Crohn's perianal fistula.
- Trial name
- NCT03056664
- Testing
- Routine drainage surgery, MSC injection 01, MSC injection 02
- Volunteers
- 3 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Pediatric Crohn's Disease
Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the "New-Drug Re-examination"
This study is a non-interventional, observational study of Humira® in the treatment of pediatric CD as per the New Drug Re-examination Guideline in Korea.
- Trial name
- NCT02578238
- Volunteers
- 143 people
- Sponsor
- AbbVie
Crohn's Disease, Ulcerative Colitis
Treatment With the Specific Carbohydrate Diet for Children With Active Crohns Disease and Ulcerative Colitis
The aim of this study is to determine the tolerability and potential efficacy of dietary therapy, the Specific Carbohydrate Diet (SCD), in pediatric patients with Crohn's disease (CD) and Ulcerative Colitis (UC).
- Trial name
- SCD (NCT02213835)
- Testing
- Specific Carbohydrate diet (SCD)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- David Suskind
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.